Brief: Aravive Announces Phase 3 Trial Design For Batiraxcept In Clear Cell Renal Cell Carcinoma

Aravive

16/05/2023 12:11

May 16 (Reuters) - Aravive Inc  ARAV.O :
    * ARAVIVE ANNOUNCES PHASE 3 TRIAL DESIGN FOR BATIRAXCEPT IN
CLEAR
CELL RENAL CELL CARCINOMA
    * ARAVIVE INC - TRIAL INITIATION ANTICIPATED IN 2H 2023 WITH
TOPLINE DATA ANTICIPATED IN 2H 2025
    * ARAVIVE INC - TRIAL INITIATION ANTICIPATED IN 2H 2023 WITH
TOPLINE DATA ANTICIPATED IN 2H 2025

Source text for Eikon:  ID:nGNX38DBMC 
Further company coverage:  ARAV.O